Tech Company Financing Transactions
OcuTerra Therapeutics Funding Round
OcuTerra Therapeutics, based in Boston, secured $35 million from private investors.
Transaction Overview
Company Name
Announced On
11/10/2021
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds will support the DR-EAM (Diabetic Retinopathy - Early Active Management) Phase 2 study of OTT166 in patients with moderate to severe non-proliferative and mild proliferative diabetic retinopathy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
50 Milk St. 16th Floor
Boston, MA 02109
USA
Boston, MA 02109
USA
Phone
Website
Email Address
Overview
OcuTerra Therapeutics, Inc. is a clinical stage company developing innovative drugs to treat ophthalmic diseases for which the current standard of care does not prevent or control the progression of disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kerrie Brady
Chief Medical Officer
David Tanzer
VP - Bus. Development
Scott Edwards
Browse more venture capital transactions:
Prev: 11/10/2021: Curated venture capital transaction
Next: 11/10/2021: Contrast Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs